Osteoarticular osteoarthritis is a chronic degenerative disease that affects the joints, particularly in older individuals, negatively impacting their quality of life. Current therapies only relieve symptoms and manage pain but do not offer a regenerative solution.
To address this need, the PROTICULAR project was launched with an initial meeting on February 14, 2025, at the Vall d’Hebron Research Institute (VHIR). The consortium includes Inves BioFarm (coordinator), Leitat, and VHIR, working together to develop an effective and safe injectable combining growth factors and hyaluronic acid for joint tissue regeneration, focusing on knee injuries.
Un mètode innovador per a la regeneració articular
The project focuses on an innovative method for encapsulating growth factors, preserving their activity for a longer period. The resulting formula will be evaluated in in vitro cellular models for optimization and later in an in vivo sheep model. Finally, a clinical study will be conducted to assess its efficacy in patients with knee osteoarthritis.
This project is part of the PCPP 2023 program and is funded under reference CPP2023-010897, with the support of:
